1. Carter BJ. The growth cycle of adeno-associated virus. In: Tjissen P, Ed. Handbook of Parvoviruses. Vol. I. Boca Raton: CRC Press, 1989:55-168.

2. Muzyczka N, Berns KI. AAV replication. In: Fields BN, Knipe DM, Howley PM, Eds. Virology. New York: Raven Press, 2001:2327-2360.

3. Carter BJ. Parvoviruses as vectors. In: Tjissen P, Ed. Handbook of Parvoviruses II. Boca Raton: CRC Press, 1989: 155-168.

4. Muzyczka N. Use of adeno-associated virus as a generalized transduction vector in mammalian cells. Curr Top Microbiol Immunol 1992; 158:97-129.

5. Carter BJ. Adeno-associated virus vectors. Curr Opin Biotech-nol 1992; 3:533-539.

6. Flotte TR, Carter BJ. Adeno-associated virus vectors for gene therapy. Gene Ther 1995; 2:357-362.

7. Hallek M, Girod A, Braun-Flaco M, Clemens-Martin W, Bogedin C, Horer M. Recombinant adeno-associated virus vectors. Curr Res Molec Therapeut 1998; 1:417-430.

8. Flotte TR, Carter BJ, Conrad CK, Guggino WB, Reynolds TC, Rosenstein BJ, Taylor G, Walden S, Wetzel R. A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther 1996; 7: 1145-1159.

9. Wagner JA, Messner AH, Moran ML, Daifuku R, Desch JK, Manley S, Norbash AM, Conrad CK, Friborg S, Reynolds T, Guggino WB, Moss RB, Carter BJ, Wine JJ, Flotte TR, Gardner P. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope 1999; 109:266-274.

10. Wagner JA, Nepomuceno IB, Messner AH, Moran ML, Bat-son EP, DiMiceli S, Brown BW, Desch JK, Norbash AM, Conrad CK, Guggino WB, Flotte TR, Wine JJ, Carter BJ, Moss RB, Gardner P. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in CF patients with antrostomies. Hum Gene Ther 2002; 13:1349-1359.

11. Aitken ML, Moss RB, Waltz DA, Dovey ME, Tonelli MR, McNamara SC, Gibson RL, Ramsey BW, Carter BJ, Reynolds TC. A phase I study of aerosolized administration of tgAAVCF to CF subjects with mild lung disease. Hum Gene Ther 2001; 12:1907-1916.

12. Kay MA, Manno CS, Rogni MV, Larson PJ, Couto LB, McClelland A, Chen AJ, Tai SJ, Herzog RW, Arruda V, John son F, Scallen C, Flake AW, High KA. Evidence for gene transfer and expression of factor IX in hemophilia B patients treated with an AAV vector. Nat Genet 2000; 24:257-261.

13. Stedman H, Mendell J, Wilson JM, Finke R, Kleckner A-L. Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy with a-, ß-, 7-, or 8-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors. Hum Gene Ther 2000; 11:777-790.

14. Carter BJ. Adeno-associated virus and adeno-associated virus vectors for gene delivery. In: Templeton NS, Lasic DD, Eds. Gene Therapy: Therapeutic Mechanisms and Strategies. New York: Marcel Dekker, 2000:41-49.

15. Rabinowitz JE, Samulski R. Adeno-associated virus expression systems for gene transfer. Curr Opin Biotechnol 1998; 9: 470-475.

16. Summerford C, Samulski RJ. Adeno-associated viral vectors for gene therapy. Biogenic Amines 1998; 4:451-475.

17. Xie Q, Bu W, Hare HJ, Somasundaram T, Azzi A. The atomic structure of adeno-associated virus (AAV-2), a vector for gene therapy. Proc Natl Acad Sci USA 2002; 99:10405-10410.

18. Rabinowitz JE, Samulski RJ. Building a better vector: Manipulation of AAV virions. Virology 2000; 278:301-308.

19. Atchison RW, Casto BC, Hammon McD. Adenovirus-associ-ated defective virus particles. Science 1965; 49:754-756.

20. Hoggan MD, Blacklow NR, Rowe WP. Studies of small DNA viruses found in various adenovirus preparations: Physical, biological and immunological characteristics. Proc Natl Acad Sci USA 1966; 55:1467-1472.

21. Blacklow NR. Adeno-associated viruses of humans. In: Pat-tison JR, Ed. Parvoviruses and Human Disease. Boca Raton: CRC Press, 1988:165-174.

22. Srivastava A, Lusby EW, Berns KI. Nucleotide sequence and organization of adeno-associated virus 2 genome. J Virol 1983; 45:555-564.

23. Miramatsu S, Mizukami H, Young N, Brown KE. Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. Virology 1996; 221:208-217.

24. Chiorini JA, Yang L, Liu Y, Safer B, Kotin RM. Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J Virol 1967; 71:6823-6833.

25. Xiao W, Chirmule N, Berta SC, McCullough B, Gao G, Wilson JM. Gene therapy vectors based on adeno-associated virus type 1. J Virol 1999; 73:3994-4003.

26. Chiorini J, Yang L, Liu Y, Safer B, Kotin R. Cloning and characterization of adeno-associated virus type 5. J Virol 1999; 73:1309-1319.

27. Bantel-Schaal U, Delius H, Schmidt R, zur Hausen H. Human adeno-associated virus type 5 is only distally related to other known primate helper-dependent parvoviruses. J Virol 1999; 73:939-947.

28. Georg-Fries B, Biederlack S, Wolf L, zur Hausen H. Analysis of proteins, helper-dependence and seroepidemiology of a new human parvovirus. Virology 1984; 134:64-71.

29. Parks WP, Melnick JL, Rongey R, Mayor HD. Physical assays and growth cycle studies of a defective adeno satellite virus. J Virol 1967; 1:171-176.

30. Rutledge EA, Halbert CL, Russell DW. Infectious clones of vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol 1998; 72:309-319.

31. Gao G, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002; 99:11854-11859.

32. Beck SE, Jones LA, Chesnut K, Walsh SM, Reynolds TC, Carter BJ, Askin FB, Flotte TR, Guggino WB. Repeated deliv ery of adeno-associated virus vectors to the rabbit airway. J Virol 1999; 73:9446-9455.

33. Carter BJ. The promise of adeno-associated virus vectors. Nat Biotechnol 1996; 14:1725-1726.

34. Hoggan MD, Thomas GF, Johnson FB. Continuous carriage of adenovirus-associated virus genome in cell culture in the absence of helper adenovirus. Proc Fourth Lepetit Colloqium. North Holland. Amsterdam:41-47.

35. McLauglin SK, Collis P, Hermonat PL, Muzyczka N. Adeno-associated virus general transduction vectors: Analysis of proviral structure. J Virol 1998; 62:1963-1973.

36. Kotin RM, Siniscalco M, Samulski RJ, Zhu XD, Hunter L, Laughlin CA, McLaughlin S, Muzyczka N, Rocchi M, Berns KI. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 1990; 87:2211-2215.

37. Samulski RJ, Zhu X, Xiao S, Brook JD, Housman DE, Epstein N, Hunter LA. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 1991; 10: 3941-3950.

38. Weitzman MD, Kyostio SRM, Kotin RM, Owens RA. Adeno-associated virus (AAV) rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc Natl Acad Sci USA 1994; 91:5808-5812.

39. Linden RM, Ward P, Giraud C, Winocour E, Bern KI. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 1996; 93:11288-11294.

40. Young SM, McCarty DM, Degtyareva N, Samulski RJ. Role of adeno-associated virus rep protein and human chromosome 19 in site-specific recombination. J Virol 2000; 74: 3953-3966.

41. Kearns WG, Afione SA, Fulmer SB, Pang MG, Erikson D, Egan L, Landrum MJ, Flotte TR, Cutting GR. Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line. Gene Ther 1996; 3:748-755.

42. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72:1438-1445.

43. Summerford C, Bartlett JS, Samulski RJ. aVß5 Integrin: A co-receptor for adeno-associated virus type 2 infection. Nat Med 1999; 5:78-82.

44. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-asociated virus 2. Nat Med 1999; 5:71-77.

45. Goldman M, Su Q, Wilson JM. Gradient of RGD-dependent entry of adenoviral vector in nasal and intrapulmonary epithe-lia: Implications for gene therapy of cystic fibrosis. Gene Ther 1996; 3:811-818.

46. Duan D, Yue Y, McCray PB, Engelhardt JF. Polarity influences the efficiency of recombinant adeno-associated virus infection in differentiated airway epithelia. Hum Gene Ther 1998; 9:2761-2776.

47. Seisenberger G, Reid MU, Endress T, Buning H, Hallek M, Brauchle C. Real-time single-molecule imaging of the infection pathway of an adeno-associated virus. Science 2001; 294: 1029-1932.

48. Hansen J, Qing K, Srivastava A. Adeno-associated virus type 2 mediated gene transfer: Altered endocytotic processing enhances transduction efficiency. J Virol 2001; 75:4080-4090.

49. Bantel-Schaal U, Hub B, Kartenbeck J. Endocytosis of adeno-associated virus type 5 leads to accumulation of virus particles in the Golgi compartment. J Virol 2002; 76:2340-2349.

50. Yan Y, Zak R, Luxton GWG, Ritchie TC, Bantel-Schaal U, Engelhardt JF. Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J Virol 2002; 76:2043-2053.

Flotte TR, Afione SA, McGrath SA, Conrad C, Zeitlin PL, Guggino WB, Carter BJ. In vivo delivery of adeno-associated vectors expressing the cystic fibrosis transmembrane conductance regulator to the airway epithelium. Proc Natl Acad Sci USA 1993; 93:10163-10617.

Afione SA, Conrad CK, Kearns WG, Chunduru S, Adams R, Reynolds TC, Guggino WB, Cutting GR, Carter BJ, Flotte TR. In vivo model of adeno-associated virus vector persistence and rescue. J Virol 1996; 70:3235-3241. Kaplitt MG, Leone P, Samulski RJ, Xiao X, Pfaff D, O'Malley KL, During M. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994; 8:148-154. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associ-ated virus vector. J Virol 1996; 70:8098-8108. Kessler PD, Podsakoff GM, Chen X, McQuiston SA, Colosi PC, Matelis LA, Kurtzman GJ, Byrne B. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 1996; 93:14082-14087.

Koerberl DD, Alexander IE, Halbert CL, Russell DW, Miller AD. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of AAV vectors. Proc Natl Acad Sci USA 1997; 94:1426-1431. Ponnazhagan S, Mukherjee P, Yoder MC, Wang X-S, Zhou SZ, Kaplan J, Wadsworth S, Srivastava A. Adeno-associated virus type 2-mediated gene transfer in vivo: Organ-tropism and expression of transduced sequences in mice. Gene 1997; 190:203-210.

Zadori Z, Szelei J, Lacoste M-C, Li Y, Gariepy S, Raymond P, Allaire M, Nabi IR, Tjissen P. A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell 2001; 1:291-302. Blacklow NR, Hoggan MD, Rowe WP. Immunofluorescent studies on the potentiation of adenovirus-associated virus by adenovirus 7. J Exp Med 1967; 125:755-762. Crawford LV, Follett EAC, Burdon MG, McGeoch DJ. The DNA of a minute virus of mice. J Gen Virol 1969; 4:37-48. Rose JA, Berns KI, Hoggan MD, Koczot FJ. Evidence for a single-stranded adenovirus-associated virus genome: Formation of a DNA density hybrid upon release of viral DNA. Proc Natl Acad Sci USA 1969; 64:863-869. Carter BJ, Khoury G, Denhardt DT. Physical map and strand polarity of specific fragments of adeno-associated virus DNA produced by endonuclease R.EcoRI. J Virol 1975; 16: 559-568.

Smuda JW, Carter BJ. Adeno-associated viruses having nonsense mutations in the capsid gene: Growth in mammalian cells having an inducible amber suppressor. Virology 1991; 84:310-318.

Carter BJ, Mendelson E, Trempe JP. AAV DNA replication, integration and genetics. In: Tjissen P, Ed. Handbook of Par-voviruses I. Boca Raton: CRC Press, 1989:169-226. Myers MW, Carter BJ. Adeno-associated virus assembly. Virology 1980; 102:71-82.

King J, Dubielzig D, Grimm D, Kleinschmidt J. DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into pre-formed capsids. EMBO J 2001; 20:3282-3291. Redemann B, Mendelson E, Carter BJ. Adeno-associated virus rep protein synthesis during productive infection. J Virol 1998; 63:873-888.

Carter BJ. Adeno-associated virus helper functions. In: Tjissen P, Ed. Handbook of Parvoviruses I. Boca Raton: CRC Press, 1989:255-282.

Perriera DJ, McCarty DM, Muzyczka N. The adeno-associated virus (AAV) rep protein acts as both a repressor and an activa tor to regulate AAV transcription during a productive infection. J Virol 1997; 71:1079-1088.

70. Samulski RJ, Berns KI, Tan N, Muzyczka N. Cloning of infectious adeno-associated virus into pBR322: Rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci USA 1982; 79:2077-2081.

71. Laughlin CA, Tratschin JD, Coon H, Carter BJ. Cloning of infectious adeno-associated virus genomes in bacterial plasmids. Gene 1983; 23:65-73.

72. Yang Q, Chen F, Trempe JP. Characterization of cell lines that inducibly express the adeno-associated virus rep proteins. J Virol 1994; 68:4847-4856.

73. Hernandez YJ, Wang J, Kearns WG, Wiler S, Poirer A, Flotte TR. Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a non-human primate model. J Virol 1999; 73:8549-8558.

74. Russell DW, Hirata RK. Human gene targeting by viral vectors. Nat Genet 1998; 18:325-330.

75. Fisher KJ, Jooss K, Alston J, Yang Y, Haecker SH, High K, Pathak R, Raper S, Wilson LM. Recombinant adeno-associ-ated virus vectors for muscle directed gene therapy. Nat Med 1997; 3:306-312.

76. Herzog RW, Hagstrom JN, Kung S-H, Tai SJ, Wilson JM, Fisher KJ, High KA. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA 1997; 94:5804-5809.

77. Snyder RO, Spratt SK, Lagarde C, Bohl C, Kaspar B, Sloan B, Cohen LK, Danos O. Efficient and stable adeno-associated virus-mediated transduction of the skeletal muscle of adult immunocompetent mice. Hum Gene Ther 1997; 8:1891-1900.

78. Miao CH, Snyder RO, Schowalter DB, Patijn GA, Donahue

B, Winther B, Kay MA. The kinetics of rAAV integration into the liver. Nat Genet 1998; 19:13-14.

79. Duan D, Sharma P, Yang J, Yue Y, Dudus L, Zhang Y, Fisher KJ, Engelhardt JF. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol 1998; 72:8568-8577.

80. Duan D, Sharma P, Dudus L, Zhang Y, Sanlioglu S, Yan Z, Yue Y, Ye Y, Lester R, Yang J, Fisher KJ, Engelhardt JF. Formation of adeno-associated virus circular genomes is differentially regulated by adenovirus E4 orf6 and E2A gene expression. J Virol 1999; 73:161-169.

81. Vincent-Lacaze N, Snyder RO, Gluzman R, Bohl D, Lagarde

C, Danos O. Structure of adeno-associated virus vector DNA following transduction of the skeletal muscle. J Virol 1999; 73:1949-1955.

82. McKeon C, Samulski RJ. NIDDK workshop on AAV vectors: Gene transfer into quiescent cells. Hum Gene Ther 1996; 7: 1615-1619.

83. Nakai H, Yant SR, Storm TA, Fuess S, Meuse L, Kay MA. Extra-chromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduc-tion in vivo. J Virol 2001; 75:6969-6976.

84. Schnepp BC, Clark KR, Klemanski DL, Pacak CA, Johnson PR. Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol 2003; 77:3495-3504.

85. Surosky RT, Urabe M, Godwin SG, McQuiston SA, Kurtzman GJ, Ozawa K, Natsoulis G. Adeno-associated virus rep proteins target DNA sequences to a unique locus in the human genome. J Virol 1997; 71:7951-7959.

86. Palombo F, Monciotti A, Recchia A, Cortese R, Ciliberto G, La Monica N. Site-specific integration in mammalian cells mediated by a new hybrid baculovirus-adeno-associated virus vector. J Virol 1998; 72:5025-5034.

87. Recchia A, Parks RJ, Lamartina S, Toniatti C, Pieroni L, Pa-lombo F, Graham FL, Cortese R, La Monica N. Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proc Natl Acad Sci USA 1999; 96:2615-2620.

88. Hirata R, Chamberlain J, Dong R, Russell DW. Targeted transgene insertion into human chromosomes by adeno-associ-ated virus vectors. Nat Biotechnol 2002; 20:735-737.

89. Yakobson B, Hrynko TA, Peak MJ, Winocour E. Replication of adeno-associated virus in cells irradiated with UV light at 254 nm. J Virol 1988; 63:1023-1030.

90. Bantel-Schaal U, zur Hausen H. Adeno-associated viruses inhibit SV40 DNA amplification and replication of herpes simplex virus in SV40-transformed hamster cells. Virology 1988; 164:64-74.

91. Flotte TR, Zeitlin PL, Solow R, Afione S, Owens RA, Mar-kakis D, Drum M, Guggino WB, Carter BJ. Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J Biol Chem 1993; 268:3781-3790.

92. Peel AL, Zolotukhin S, Schrimsher GW, Muzyczka N, Reier PJ. Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Ther 1997; 4:16-24.

93. Flannery JG, Zolotukhin S, Vaquero MI, LaVail MM, Muzyczka N, Hauswirth WW. Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci USA 1997; 94:6916-6921.

94. Rendahl KC, Quiroz D, Ladner M, Coyne M, Manning WC, Escobedo LA. Tightly regulated long-term erythropoietin expression in vivo using tet-inducible recombinant adeno-as-sociated viral vectors. Hum Gene Ther 2002; 13:335-342.

95. Favre D, Blouin V, Provost N, Spisek R, Porrot F, Bohl D, Marme F, Cherel Y, Salvetti A, Hurtrel B, Heard J-M, Riviere Y, Mouiller P. Lack of an immune response against the tetracy-cline-dependent transactivator correlates with long-term doxy-cycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus. J Virol 2002; 76:11605-11611.

96. Aurrichio A, Rivera VM, Clackson T, O'Connor EE, Magure AM, Tolentino MJ, Bennett J, Wilson JM. Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye. Mol Ther 2002; 6:238-242.

97. Song S, Morgan M, Ellis T, Poirier A, Chesnut K, Wang J, Brantly M, Muzyczka N, Byrne BJ, Atkinson M, Flotte TR. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci USA 1998; 95:14384-14388.

98. Allen JA, Debelak DJ, Reynolds TC, Miller AD. Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by non-homologous recombination during AAV vector production. J Virol 1997; 71:6816-6822.

99. Wang XS, Khuntirat B, Qing K, Ponnazhagan S, Kube DM, Zhou S, Dwarki VJ, Srivastava A. Characterization of wildtype adeno-associated virus type 2-like particles generated during recombinant viral vector production and strategies for their elimination. J Virol 1998; 72:5472-5480.

100. Fan P-D, Dong J-Y. Replication of rep-cap genes is essential for the high-efficiency production of recombinant AAV. Hum Gene Ther 1997; 8:87-98.

101. Vincent K, Piraino ST, Wadsworth SC. Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products. J Virol 1997; 71:1897-1905.

102. Li J, Samulski RJ, Xiao X. Role for highly regulated rep gene expression in adeno-associated virus vector production. J Virol 1997; 71:5236-5243.

103. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72:2224-2232.

104. Matushita T, Elliger S, Elliger C, Podskaoff G, Villareal K, Kurtzman GJ, Iwaki Y, Colosi P. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther 1998; 5:938-945.

105. Salvetti AS, Orev S, Chadeuf G, Favre D, Cherel Y, Champion-Arnaud P, David-Ameline J, Mouillier P. Factors influencing recombinant adeno-associated virus production. Hum Gene Ther 1998; 9:695-706.

106. Grimm D, Kern A, Rittnet K, Kleinschmidt AJ. Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum Gene Ther 1998; 9:2745-2760.

107. Samulski RJ, Chang LS, Shenk TE. Helper-free stocks of recombinant adeno-associated viruses: Normal integration does not require viral gene expression. J Virol 1989; 63:3822-3828.

108. Flotte TR, Barrazza-Ortiz X, Solow R, Afione SA, Carter BJ, Guggino WB. An improved system for packaging recombinant adeno-associated virus vectors capable of in vivo transduction. Gene Ther 1995; 2:39-47.

109. Clark KR, Voulgaropoulou F, Fraley DM, Johnson PR. Cell lines for the production of recombinant adeno-associated virus. Hum Gene Ther 1995; 6:1329-1341.

110. Liu X, Voulgaropoulou F, Chen R, Johnson PR, Clark KR. Selective rep-cap gene amplifications as a mechanism for high-titer recombinant AAV production from stable cell lines. Mol Ther 2000; 2:394-403.

111. Gao G-P, Qu G, Faust LZ, Engdahl RK, Xiao W, Hughes JV, Zoltick PW, Wilson JM. High-titer adeno-associated viral vectors from a rep/cap cell line and hybrid shuttle virus. Hum Gene Ther 1998; 9:2353-2362.

112. Liu XL, Clark KR, Johnson PR. Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant virus. Gene Ther 1999; 6:293-299.

113. Fisher KJ, Kelley WM, Burda JF, Wilson JM. A novel adeno-virus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome. Hum Gene Ther 1996; 7:2079-2087.

114. Lieber A, Steinwarder DS, Carlson CA, Kay MA. Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all genes. J Virol 1999; 73:9314-9324.

115. Sandolon Z, Gnatenko DM, Bahou WF, Hearing P P. Adeno-associated (AAV) rep protein enhances the generation of a recombinant mini-adenovirus utilizing an Ad/AAV hybrid virus. J Virol 2000; 74:10381-10389.

116. Inoue I, Russell DW. Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors. J Virol 1998; 72:7024-7031.

117. Conway JE, Zolotukhin S, Muzyczka N, Hayward GS, Byrne BJ. Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing rep and cap. J Virol 1997; 71: 8780-8789.

118. Wustner JT, Arnold S, Lock M, Richardson JC, Himes VB, Kurtzman G, Peluso RW. Production of recombinant adeno-associated type 5 (rAAV5) vectors using recombinant herpes simplex viruses containing rep and cap. Mol Ther 2002; 6: 510-518.

119. Johnston KM, Jacoby D, Pechan PA, Fraefel C, Borghesani P, Schuback D, Dunn RJ, Smith FI, Breakfield XO. HSV/ AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum Gene Ther 1997; 8:359-370.

120. Zhang X, de Alwis M, Hart SL, Fitzke FW, Inglis SC, Bours-nell MEG, Levinsky RL, Kinnon C, Ali RR, Thrasher AJ. High-titer recombinant adeno-associated virus production from replicating amplicons and herpes virus deleted for glycoprotein H. Hum Gene Ther 1999; 10:2527-2537. Urabe M, Ding C, Kotin RM. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther 2002; 13:1935-1943.

Cao L, Liu Y, During M, Xiao W. High-titer wild-type free recombinant adeno-associated virus vector production using intron-containing helper plasmids. J Virol 2000; 74: 11456-11463.

Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, Samulski RJ, Muzyczka N. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 1999; 6:973-985. Hermans WT, ter Brakke O, Dijkhuisen A, Sonnemans MA, Grimm D, Kleinschmidt JA, Verhaagen J. Purification of recombinant adeno-associated virus by iodixonal gradient ultra-centrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system. Hum Gene Ther 1999; 10:1885-1891.

Tamayose K, Hirai Y, Shimada T. A new strategy for large-scale preparation of high titer recombinant adeno-associated virus vectors by using packaging cell lines and sulfonated cellulose column chromatography. Hum Gene Ther 1996; 7: 507-513.

Clark RW, Liu X, McGrath JP, Johnson PR. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild type viruses. Hum Gene Ther 1999; 10:1031-1039.

Gao G, Gu G, Burnhan MS, Huang J, Chirmule N, Joshi B, Yu Q-C, Marsh IA, Conceicao CM, Wilson JM. Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo. Hum Gene Ther 2000; 11:2079-2091.

DebelakDJ, Fisher J, Iuliano S, SesholtzD, Sloane DL, Atkinson EM. Cation exchange high-performance liquid chromatog-raphy of recombinant adeno-associated virus type 2. J Chro-matogr 2000; 740:195-202.

O'Riordan CR, Lachappelle AL, Vincent KA, Wadsworth SC. Scaleable chromatographic purification process for recombinant adeno-associated virus (rAAV). J Gene Med 2000; 2: 444-454.

Drittanti L, Jenny C, Poulard K, Samba A, Manceau P, Soria N, Vincent N, Danos O, Vega M. Optimized helper virus-free production of high quality adeno-associated virus vectors. J Gene Med 2001; 3:59-71.

Kaludov N, Handelman B, Chiorini JA. Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography. Hum Gene Ther 2002; 13:1235-1243. Brument N, Morenweisser R, Blouin V, Toublanc E, Raim-baud I, Cherel Y, Folliot S, Gaden F, Boulanger P, Kroner-Lux G, Moullier P. A versatile and scalable two-step ion-exchange chromatography process for the purification of recombinant adeno-associated virus serotypes 2 and 5. Mol Ther 2002; 6: 678-688.

Aurrichio A, Hildinger M, O'Connor E, Gao G-P, Wilson JM. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther 2001; 12:71-76.

Aurrichio A, O'Connor E, Hildinger M, Wilson LM. A singlestep affinity column for purification of serotype-5 based adeno-associated viral vectors. Mol Ther 2001; 4:372-379. Salvetti A, Oreve A, Cahdeuf G, Favre D, Cherel Y, Champion-Arnaud P, David-Ameline J, Moullier P. Factors influencing recombinant adeno-associated virus production. Hum Gene Ther 1998; 9:695-706.

136. Bartlett JS, Samulski RJ. Methods for construction and propagation of recombinant adeno-associated virus vectors. In: Rob-bins P, Ed. Methods in Molecular Medicine, Gene Therapy Protocols: Humana Press, 2000:25-40.

137. Clark KR, Voulgaropoulou F, Johnson PR. A stable cell line carrying adenovirus inducible rep and cap genes allows fore infectivity titration of adeno-associated virus vectors. Gene Ther 1996; 3:1124-1132.

138. Atkinson EM, Debelak DJ, Hart LA, Reynolds TC. A high-throughput hybridization method for titer determination of viruses ands gene therapy vectors. Nucleic Acids Res 1998; 26: 2821-2823.

139. Grimm DR, Kern A, Pawlita M, Ferrari F, Samulski R, Kleinschmdit JA. Titration of AAV-2 particles via a novel capsid ELISA: Packaging of genomes limits production of recombinant AAV-2. Gene Ther 1999; 6:1322-1330.

140. Samulski RJ. Antibody to AAV serotype 1 neutralizes AAV serotype 6. personal communication, 2003.

141. Walters RW, Yi SM, Keshavjee S, Brown KE, Welsh MJ, Chiorini JA, Zabner J. Binding of adeno-associated virus type

5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem 2001; 276:20610-20616.

142. Di Pasquale G, Scuderio D, Monks A, Chiorini JA. Identification of PDFGR as a receptor for AAV5 transduction by comparative gene expression analysis using cDNA microarrays. Mol Ther 2003; 7:334.

143. Chorini JA, Afione SA, Kotin RM. Adeno-associated virus (AAV) type 5 rep protein cleaves a unique terminal resolution site compared to other AAV serotypes. J Virol 1999; 73: 4293-4298.

144. Chao H, Liu Y, Rabinowitz J, Li C, Samulski RJ, Walsh CE. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2000; 2:619-623.

145. Rabinowitz J, Rolling F, Li C, Conrath H, Xiao W, Xiao X, Samulski RJ. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV sero-types enables transduction with broad specificity. J Virol 2002; 76:791-801.

146. Hildinger M, Aurricchio A, Gao G, Wang L, Chirmule N, Wilson JM. Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. J Virol 2001; 75:6199-6203.

147. Zabner J, Seiler M, Walters R, Kotin RM, Fulgeras W, Davidson BL, Chiorini AJ. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelial cells and facilitates gene transfer. J Virol 2000; 74:3652-3658.

148. Aurichio A, O'Connor E, Weiner D, Gao G-P, Hildinger M, Wang L, Calcedo R, Wilson JM. Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. J Clin Invest 2002; 110:499-504.

149. Davidson B, Stein C, Heth J, Martins L, Kotin R, Derksen T, Zabner J, Rhodes A, Chiorini J. Recombinant adeno-associ-ated virus type 2, 4 and 5 vectors: Transduction of variant cell types and regions in mammalian central nervous system. Proc Natl Acad Sci USA 2000; 97:3428-3432.

150. Mingozzi F, Schuttrumpf J, Arruda VR, Liu Y, Liu Y-L, High KA, Xiao W, Herzog RW. Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector. J Virol 2002; 76:10497-10502.

151. Halbert CL, Allen JM, Miller AD. Adeno-associated virus type

6 (AAV6) vectors mediate efficient transduction of airway epithelium in mouse lungs compared to that of AAV2 vector. J Virol 2001; 75:6615-6624.

152. Halbert CL, Rutledge EA, Allen JM, Russell DW, Miller AD. Repeat transduction in the mouse lung by using adeno-associ-

ated virus vectors with different serotypes. J Virol 2000; 74: 1524-1552.

153. Maio CH, Nakai H, Thompson AR, Storm TA, Chiu W, Snyder RO, Kay MA. Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: Cell cycling does not influence hepatocyte transduction. J Virol 2000; 74:3793-3803.

154. Aurricchio A, Kobinger A, Anand G, Hildinger M, O'Connor E, McGuire AM, Wilson JM, Bennett J. Exchange of surface proteins impacts on viral vector cellular specificity and trans-duction characteristics: The retina as a model. Hum Mol Genetics 2001; 10:3075-3081.

155. Yang GS, Schmidt M, Yan Z, Lindbloom JD, Harding TC, Donohue BA, Engelhardt JF, Kotin R, Davidson BL. Virusmediated transduction of murine retina with adeno-associated virus: Effects of viral capsid and genome size. J Virol 2002; 76:7651-7660.

156. Duan D, Yue Y, Yan Z, Yang J, Engelhardt JF. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest 2000; 105:1573-1587.

157. Duan D, Li Q, Kao AW, Yue Y, Pessin JE, Engelhardt JF. Dynamin is required for recombinant adeno-associated virus type 2 infection. J Virol 1999; 73:10371-10376.

158. Bartlett JS, Wilcher R, Samulski RJ. Infectious entry pathway of adeno-associated and adeno-associated virus vectors. J Virol 2000; 74:2777-2785.

159. Douar AM, Poulard K, Stockholm D, Danos O. Intracellular trafficking of adeno-associated virus vectors: Routing to the late endosomal compartment and proteosome degradation. J Virol 2000; 75:1824-1833.

160. Sanlioglu S, Benson PK, Yang J, Atkinson EM, Reynolds T, Engelhardt JF. Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by Rac1 and phosphati-dylinositol-3 kinase activation. Virology 2000; 74:9184-9196.

161. Bartlett JS, Wilcher R, Samulski RJ. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol 2000; 74:2777-2785.

162. Hansen J, Qing K, Kwon HJ, Mah C, Srivastava A. Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. J Virol 2000; 74:992-996.

163. Xiao W, Warrington KH, Hearing P, Hughes J, Muzyczka N. Adenovirus-facilitated nuclear translocation of adeno-associ-ated virus type 2. J Virol 2002; 76:11505-11517.

164. Hansen J, Qing K, Srivastava A. Infection of purified nuclei by adeno-associated virus 2. Mol ther 2001; 4:289-296.

165. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996; 70: 3227-3234.

166. Fisher KJ, Gao GP, Weitzman MD, DeMatteo R, Burda JF, Wilson JM. Transduction with recombinant adeno-associated virus vectors for gene therapy is limited by leading strand synthesis. J Virol 1996; 70:520-532.

167. Russell DW, Alexander IE, Miller AD. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-asso-ciated virus vectors. J Virol 1996; 92:5719-5723.

168. Sanioglu S, Duan D, Engelhardt JF. Two independent molecular pathways for recombinant adeno-associated virus genomes conversion occur after UV-C and E4orf6 augmentation of transduction. Hum Gene Ther 1999; 10:591-602.

169. Qing K, Hansen J, Weigel-Kelley KA, Tan M, Zhou S, Srivas-tava A. Adeno-associated virus type 2-mediated gene transfer: Role of cellular FKBP52 protein in transgene expression. J Virol 2001; 75:8968-8976.

170. Qing K, Li W, Zhong L, Tan M, Hansen J, Weigel-Kelley KA, Chen L, Yoder MC, Srivastava A. Adeno-associated virus 2-mediated gene transfer: Role of cellular T cell protein tyro-sine phosphatase in transgene expression and established cell line in vitro and transgenic mice in vivo. J Virol 2003; 77: 2741-2746.

171. Nakai H, Storm TA, Kay MA. Recruitment of single-stranded recombinant adeno-associated vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo. J Virol 2000; 74:9451-9463.

172. Hirata RK, Russell DW. Design and packaging of adeno-asso-ciated virus gene targeting vectors. J Virol 2000; 74: 4612-4620.

173. McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 2001; 8:1248-1254.

174. McCarty DM, Fu H, Samulski J. Self-complementary rAAV (scAAV) vectors overcome barriers to efficient transduction in mouse liver cells. Mol Ther 2002; 5:S3.

175. Whang Z, Ma H, Sun L, Zhiang J, Li J, Xiao X. Double stranded AAV offers far more than doubled gene transfer. Mol Ther 2002; 5:S3.

176. Duan D, Yan Z, Yue Y, Engelhardt JF. Structural analysis of adeno-associated virus transduction circular intermediates. Virology 1999; 261:8-14.

177. Yang J, Zhou W, Zhang Y, Zidon T, Ritchie T, Engelhardt JE. Concatemerization of adeno-associated virus circular genomes occurs through intermolecular recombination. J Virol 1999; 73:9468-9477.

178. Song S, Laipis P, Berns KI, Flotte T. Effect of DNA-dependent protein kinase on the molecular fate of the rAAV2 genome in skeletal muscle. Proc Natl Acad Sci USA 2000; 98: 4084-4088.

179. Nakai H, Storm TA, Kay MA. Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat Biotechnol 2000; 18: 527-532.

180. Chen Z-Y, Yant SR, He C-Y, Meuse L, Shen S, Kay MA. Linear DNAs concatemerize in vivo and result in sustained transgene expression in mouse liver. Mol Ther 2001; 3: 403-409.

181. Sanlioglu S, Benson P, Engelhardt JE. Loss of ATM function enhances recombinant adeno-associated virus transduction and integration through pathways similar to UV irradiation. Virology 2000; 268:68-78.

182. Zentilin L, Marcello A, Giacca M. Involvement of cellular double-stranded DNA break binding proteins in processing of the recombinant adeno-associated virus genome. J Virol 2001; 75:12279-12287.

183. Duan D, Yue Y, Yan Z, Engelhardt JE. A new dual vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation. Nat Med 2000; 6:595-598.

184. Yan Z, Zhang Y, Duan D, Engelhardt J JE. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci USA 2000; 97:6716-6721.

185. Sun L, Li J, Xiao X. Overcoming adeno-associated virus size limitation through viral DNA heterodimerization. Nat Med 2000; 6:599-602.

186. Halbert CL, Allen JM, Miller AD. Efficient mouse airway transduction following recombination between AAV vectors carrying parts of a larger gene. Nat Biotechnol 2002; 20: 697-701.

187. Duan D, Yue Y, Engelhardt JF. Expanding AAV packaging capacity with trans-splicing or overlapping vectors: A quantitative comparison. Mol Ther 2001; 4:383-391.

Bartlett JS, Kleinschmidt J, Boucher RC, Samulski RJ. Targeted adeno-associated virus vector transduction of nonper-missive cells mediated by a bi-specific F(aP'y)2 antibody. Nat Biotechnol 1999; 17:181-185.

Girod A, Ried M, Wobus M, Lahm H, Leike K, Kleinschmidt J, Delage G, Hallek M. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med 1999; 5:1052-1056.

Moskalenko M, Chen L, van Roey M, Donahue BA, Snyder RO, McArthur JG, Patel SD. Epitope mapping of human adeno-associated virus type 2 neutralizing anti-antibodies: Implications for gene therapy and structure. J Virol 2000; 74: 1761-1766.

Wu P, Xiao W, Conlon T, Hughes J, Agbandje-McKenna M, Ferkol T, Flotte T, Muzyczka N. Analysis of the adeno-asoci-ated type 2 (AAV2) capsid gene and construction of AAV vectors with altered tropism. J Virol 2000; 74:8635-8647. Rabinowitz JE, Xiao W, Samulski RJ. Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology 1999; 265:274-285.

Reid MU, Gorod A, Leike K, Buning H, Hallek M. Adeno-associated virus capsids displaying immunoglobulin-binding domains permit antibody-mediated vector retargeting to specific cell surface receptors. J Virol 2002; 76:4559-4566. Grifman M, Trepel M, Speece P, Baetriz-Gilbert L, Arap W, Pasquilini R, Weitzman MD. Incorporation of tumor targeting peptides into recombinant adeno-associated virus capsids. Mol Ther 2001; 3:964-970.

Shi W, Arnold GS, Bartlett JS. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV 2 vectors targeted to alternative cell-surface receptors. Hum Gene Ther 2001; 12:1697-1711. Chirmule N, Xiao W, Truneh A, Schnell M, Hughes JV, Zol-tich P, Wilson LM. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and non-human primate muscle. J Virol 2000; 74:2420-2425. Halbert CL, Standaert TA, Wilson CB, Miller AD. Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during initial exposure. J Virol 1998; 72:9795-9805. Xiao W, Chirmule N, Schnell MA, Tazelaar J, Hughes JV, Wilson JM. Route of administration determines induction of T-cell independent humoral responses to adeno-associated virus vectors. Mol Ther 2000; 1:323-329.

Brockstedt DG, Podsakoff GM, Fong L, Kurtzman G, Mueller-Ruchholtz W, Engelmann E. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin Immunol 1999; 2: 67-75.

Halbert CL, Standaert TA, Aitken ML, Alexander IE, Russell DW, Miller AD. Transduction by adeno-associated virus vectors in the rabbit airway: Efficiency, persistence and readministration. J Virol 1997; 71:5932-5941. Manning WC, Zhou S, Bland MP, Escobedo JA, Dwarki V. Transient immunosuppression allows transgene expression following readministration of adeno-associated virus vectors. Hum Gene Ther 1998; 9:477-485.

Zhang Y, Chirmule N, Gao G-P, Wilson JM. CD40-ligand dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: Role of immature dendritic cells. J Virol 2000; 74:8003-8010.

Jooss K, Yang Y, Fisher KJ, Wilson JM. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998; 72: 4212-4223.

204. Manning WC, Paliard X, Zhou S, Bland MP, Lee Ay, Hong K, Walker CM, Escobedo JA, Dwarki V. Genetic immunization with adeno-associated virus vectors expressing herpes simplex type2 glycoproteins B and D. J Virol 1997; 71: 7960-7962.

205. Fields PA, Kowalczyk DW, Arruda VR, Armstrong E, McClelland ML, Hogstrom JW, Pasi EJ, Erth HCJ, Herzog RW, High KA. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol Ther 2000; 1:225-231.

206. Conrad CK, Allen SS, Afione SA, Reynolds TC, Beck SE, Fee-Maki M, Barrazza-Ortiz X, Adams R, Askin FB, Carter BJ, Guggino WB, Flotte TR. Safety of single-dose administration of an adeno-associated virus (AAV-CFTR) vector in the primate lung. Gene Ther 1996; 3:658-668.

207. Herzog RW, Fields PA, Arruda VR, Brubaker JO, Armstrong E, McClintock D, Bellinger DA, Couto LB, Nichols TC, High KA. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther 2002; 13:1281-1291.

208. U.S. Department of Health and Human Services National Institutes of Health Recombinant DNA Advisory Committee. Minutes of meeting. Hum Gene Ther 2002; 13:1663-1673.

209. Arruda VR, Fields PA, Milner R, Wainwright L, de Miguel MP, Donovan PJ, Herzog RW, Nicholls TC, Biegel JA, Razavi M, Dake M, Huff D, Flake AW, Couto L, Kay MA, High KA. Lack of transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Mol Ther 2001; 4:586-596.

210. Favre D, Provost N, Blouin V, Blancho G, Cherel Y, Salvetti A, Moullier P. Immediate and long-term safety of recombinant adeno-associated virus injection into nonhuman primate muscle. Mol Ther 2001; 4:559-568.

211. Song S, Scott-Jorgensen M, Wang J, Poirer A, Crawford J, Campbell-Thompson M, Flotte TR. Intramuscular administration of recombinant adeno-associated virus 2 a-1 antitrypsin (rAAV-SERPINA1) vectors in a non-human primate model: Safety and immunologic aspects. Mol Ther 2002; 6:329-336.

212. de la Maza LM, Carter BJ. Inhibition of adenovirus oncogenic-ity in hamsters by adeno-associated virus DNA. J Natl Cancer Inst 1981; 67:1323-1326.

213. Raj K, Ogston P, Beard P. Virus-mediated killing of cells that lack p53 activity. Nature (London) 2001; 412:914-917.

214. Daly TM, Ohlemiller KK, Roberts MS, Vogler CA, Sands MS. Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer. Gene Ther 2001; 8:1291-1298.

215. Donsante A, Vogler C, Muzyczka N, Crawford JM, Barker J, Flotte T, Campbell-Thompson M, Daly T, Sands MS. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther 2001; 8:1343-1346.

216. Song S, Embury J, Laipis PJ, Berns KI, Crawford JM, Flotte TR. Stable therapeutic serum levels of alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associ-ated virus (AAV) vectors. Gene Ther 2001; 8:1299-1306.

217. Snyder RO, Miao C, Meuse L, Tubb J, Donahue BA, Lin H-F, Stafford DW, Patel S, Thompson AR, Nichols T, Read MS, Belliger DA, Brinkhous KM, Kay MA. Correction of hemophilia B in canine and murine models using recombinant adeno-associated vectors. Nat Med 1999; 64-69.

218. Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, Fields PA, Burton M, BNellinger DA, Read MS, Brinkhous KM, Podsakoff GM, Nichols TC, Kurtzman GJ, High KA. Long-term correction of canine hemophilia by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999; 5:56-63.

219. Monahan PE, Samulski RJ, Tazelar J, Xiao X, Nichols TC, Bellinger DA, Read MS, Walsh CE. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther 1999; 5: 40-49.

220. Maganti V, Hunter S, Peluso R, Thompson S, Lynch C, Dorner A, Schaub R, Keith J. Hemostatic correction of FVIII KO mice with intravenous administration of an AAV-FVIII vector. Blood 2002; 100:869a.

221. Burton M, Nakai H, Colosi P, Mitchell R, Couto L. Coexpres-sion of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein. Proc Natl Acad Sci USA 1999; 96:12725-12730.

222. Chao H, Sun L, Bruce A, Xiao X, Walsh CE. Expression of human factor FVIII by splicing between dimerized AAV vectors. Mol Ther 2002; 6:716-722.

223. Emery AE. The muscular dystrophies. Lancet 2002; 359: 687-695.

224. Ibraghimov-Beskrovnaya O, Ervasti JM, Leveille CJ, Slaughter CA, Sernett SW, Campbell KP. Primary structure of dys-trophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 1999; 355:696-702.

225. England SB, Nicholson LV, Johnson MA, Forrest S, Love DR, Zubrzycka-Gaarn EE, Bulman DE, Harris JB, Davies KE. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 1990; 343:180-182.

226. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darliso MG, Barnad PJ. The molecular basis of muscular dystrophy in the mdx mouse: A point mutation. Science 1989; 244: 1578-1580.

227. Phelps SF, Hauser MA, Cole NM, Rafael JA, Hinkle RT, Faulkner JA, Chamberlain JS. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet 1995; 4:1251-1258.

228. Wang B, Li J, Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci USA 2000; 7:13714-13719.

229. Fabb SA, Wells DJ, Serpente P, Dickson G. Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micro-dystrophin effectively restores the dystrophin-associated protein complex and inhibits myofiber degeneration in nude/mdx mice. Hum Mol Genet 2002; 11:733-741.

230. Harper SQ, Hauser MA, DelloRusso C, Duan D, Crawford RW, Phelps SF, Harper HA, Robinson AS, Engelhardt JF, Brooks SV, Chamberlain JS. Modular flexibility of dys-trophin: Implications for gene therapy of Duchenne muscular dystrophy. Nat Med 2002; 8:253-261.

231. Li J, Dressman D, Tsao YP, Sakamoto A, Hoffman EP, Xiao X. rAAV vector-mediated sarcoglycan gene transfer in a hamster model for limb girdle muscular dystrophy. Gene Ther 1999; 6:74-82.

232. Greelish JP, Su LT, Lankford EB, Burkman JM, Chen H, Konig SK, Mercier IM, Desjardins PR, Mitchell MA, Zheng XG, Leferovich L, Gao GP, Balice-Gordon RJ, Wilson JM, Stedman HL. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat Med 1999; 5:439-443.

233. Xiao X, Li J, Tsao YP, Dressman D, Hoffman EP, Watchko JF. Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy. J Virol 2000; 74:1436-1442.

234. Cordier L, Hack AA, Scott MO, Barton-Davis ER, Gao G, Wilson JM, McNally EM, Sweeney HL. Rescue of skeletal muscles of y-sarcoglycan-deficient mice with adeno-associ-ated virus-mediated gene transfer. Mol Ther 2000; 1:119-129.

235. Dressman D, Araishi K, Imamura M, Sasaoka T, Liu LA, En-gvall E, Hoffman EP. Delivery of a- and ß-sarcoglycan by recombinant adeno-associated virus: Efficient rescue of muscle, but differential toxicity. Hum Gene Ther 2002; 13: 1631-1646.

236. Szczypka MS, Mandel RJ, Donahue BA, Snyder RO, Leff SE, Palmiter RD. Viral gene delivery selectively restores feeding and prevents lethality of dopamine-deficient mice. Neuron 1999; 22:167-178.

237. Sanchez-Pernaute R, Harvey-White J, Cunningham J, Bankie-wicz KS. Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. Mole Ther 2001; 4: 324-330.

238. Leff SE, Spratt SK, Snyder RO, Mandel RJ. Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson's disease. Neuroscience 1999; 92:185-196.

239. Fan DS, Ogawa M, Fujimoto KI, Ikeguchi K, Ogasawara Y, Urabe M, Nishizawa M, Nakano I, Yoshida M, Nagatsu I, Ichinose H, Nagatsu T, Kurtzman GJ, Ozawa K. Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduc-tion of striatum with tyrosine hydroxylase and aromatic Lamino acid decarboxylase genes using two separate adeno-associated virus vectors. Hum Gene Ther 1998; 9:2527-2535.

240. Bankiewicz KS, Eberling JL, Kohutnicka M, Jagust W, Pivi-rotto P, Bringas J, Cunningham J, Budinger TF, Harvey-White J. Convection-enhanced delivery of AAV vector in parkinsonian monkeys: In vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 2000; 164:2-14.

241. During MJ, Samulski RJ, Elsworth JD, Kaplitt MG, Leone P, Xiao X, Li J, Freese A, Taylor JR, Roth RH, SladekJR, O'Mal-ley KL, Redmond DE. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther 1998; 5: 820-827.

242. Shen Y, Muramatsu SI, Ikeguchi K, Fujimoto KI, Fan DS, Ogawa M, Mizukami H, Urabe M, Kume A, Nagatsu I, Urano F, Suzuki T, Ichinose H, Nagatsu T, Monahan J, Nakano I, Ozawa K. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum Gene Ther 2000; 11:1509-1519.

243. Muramatsu S, Fujimoto K, Ikeguchi K, Shizuma N, Kawasaki K, Ono F, Shen Y, Wang L, Mizukami H, Kume A, Matsumura M, Nagatsu I, Urano F, Ichinose H, Nagatsu T, Terao K, Na-kano I, Ozawa K. Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthe-sizing enzymes. Hum Gene Ther 2002; 13:345-354.

244. Hou JG, Lin LF, Mytilineou C. Glial cell line-derived neuro-trophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium. J Neurochem 1996; 66:74-82.

245. Kearns CM, Gash DM. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res 1996; 672: 104-111.

246. Mandel RJ, Spratt SK, Snyder RO, Leff SE. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci USA 1997; 94:14083-14088.

0 0

Post a comment